SCHEMBL10244574

SCHEMBL10244574

CNC(=O)N1CCN(C(C)c2ccccc2OC)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
PKM P14618 2/20 0.47
MAPK1 P28482 1/20 0.47
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11886645 0.76 KDM4E (0.49) KDM4EPKMMAPK1SMN1; SMN2HTT
SCHEMBL13553399 0.75 KDM4E (0.51) KDM4ESMN1; SMN2HTTMEN1KMT2A
SCHEMBL31709303 0.74 GAA (0.58) KDM4ETDP1MAPK1POLBMEN1
SCHEMBL13185834 0.73 KDM4E (0.73) KDM4ETDP1PKMMAPK1POLB
SCHEMBL10471384 0.73 TSHR (0.45) KDM4ETDP1POLBSMN1; SMN2ALDH1A1
SCHEMBL10471383 0.73 TSHR (0.45) KDM4ETDP1POLBSMN1; SMN2ALDH1A1
SCHEMBL10244724 0.73 MCHR1 (0.48) ALDH1A1HRH3CA1CA2MAPT
SCHEMBL11886647 0.73 CHRM2 (0.46) KDM4ESMN1; SMN2HSD17B10MAPT
SCHEMBL10245676 0.73 KMT2A (0.48) MAPK1SMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL13553420 0.72 CHRM2 (0.51) HTTMEN1KMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KDM4E 128/4885TDP1 2672/4885PKM 4614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.